|

Title: Stabilization of enzymes during freezing
United States Patent: 6,579,707
Issued: June 17, 2003
Inventors: Fitzgerald; Stephen Peter (Co. Antrim, GB);
Campbell; John (Co. Antrim, GB); Lamont; John Victor (Co. Antrim, GB); King;
Marlene (Co. Antrim, GB)
Assignee: Randox Laboratories Ltd. (Northern Ireland, GB)
Appl. No.: 949757
Filed: September 12, 2001
Abstract
A method for stabilizing an enzyme during freezing, wherein the enzyme is
in a zwitterionic buffer solution. The zwitterionic buffer is able to
maintain the activity of the enzyme during freezing and thawing.
DESCRIPTION OF THE INVENTION
The present invention relies on the use of zwitterionic buffers to prepare
the liquid reagent formulations. Zwitterionic buffers are sometimes referred
to as "Goods" buffers (Good et al, Biochemistry, 1966; 5:467) and are
commercially available. The buffers are generally zwitterionic aliphatic
amines, with the majority being either substituted glycines or taurines. The
buffers are distinct from the phosphate buffers used in the prior art to
stabilise glucose oxidase reagents.
Suitable buffers which may be used in the present invention include Mops
(3-[N-Morpholino]propanesulphonic acid), Mopso
(3-[N-Morpholino]-2-hydroxypropanesulphonic acid) and Hepes
(N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid]). Each of these
buffers is available from commercial sources. Alternative zwitterionic
buffers will be apparent to the skilled person.
The preparation of the buffer with the enzyme will be apparent to the
skilled person, and the buffer will typically be prepared at a concentration
of 20-250 mmol/l. Preferably, the buffer solution will be prepared with a pH
of 7.
Although the buffers will prevent inactivation of the enzymes on freezing,
it is preferred that the solutions are stored at 4oC.
The buffers may be used to stabilise any enzyme against the effects of
freezing. In a preferred embodiment, the enzyme is glucose oxidase or
horse-radish peroxidase. The enzymes may be the only active molecule present
in the buffer solution. For example, the solution will not contain
triglycerides or cholesterol which are sometimes present in some diagnostic
kits which require peroxidase. The solutions may also be free from
polysaccharides or oligosaccharides, i.e. sugars.
The following Example illustrates the invention.
EXAMPLE
Four different formulations, containing either Mops, phosphate buffer or a
combination of both were prepared according to the formulations described
below. Glucose oxidase (EC 1.1.3.4) from Aspergillus niger and horse-radish
peroxidase (EC 1.11.1.7) were used. The other components of each formulation
were included to promote the colourimetric glucose reaction or to help
stabilise the reagents.
Formulation A
50 mmol/l Mops buffer
20 KU/l glucose oxidase
1.6 KU/l Peroxidase
11.0 mmol/l Phenol
0.05% sodium azide
0.03% polyvinylpyrrolidine
0.77 mmol/L 4-amino antipyrine
The pH is adjusted to 7.0 with sodium hydroxide and/or hydrochloric acid.
Formulation B
150 mmol/l Mops buffer
20 KU/l glucose oxidase
1.6 KU/l Peroxidase
11.0 mmol/l Phenol
0.05% sodium azide
0.03% polyvinylpyrrolidine
0.77 mmol/L 4-amino antipyrine
The pH is adjusted to 7.0 with sodium hydroxide and/or hydrochloric acid.
Formulation C
50 mmol/l Mops buffer
19.5 mmol/l sodium dihydrogen phosphate
30.5 mmol/l disodium hydrogen orthophosphate
19.20 KU/l glucose oxidase
1.6 KU/l Peroxidase
11.0 mmol/l Phenol
0.04% sodium azide
0.03% polyvinylpyrrolidine
0.77 mmol/L 4-amino antipyrine
The pH is adjusted to 7.0 with sodium hydroxide and/or hydrochloric acid.
Formulation D (Control without Mops Buffer)
39 mmol/l sodium dihydrogen phosphate
61 mmol/l disodium hydrogen orthophosphate
20 KU/l glucose oxidase
1.6 KU/l Peroxidase
11.0 mmol/l Phenol
0.04% sodium azide
0.03% polyvinylpyrrolidine
0.77 mmol/L 4-amino antipyrine
The pH was adjusted to 7.0 with sodium hydroxide and/or hydrochloric acid.
All of the formulations were frozen at -20oC. for 2 weeks and the
activity of each enzyme measured after thawing. Peroxidase activity was
measured using the method of Theorell, Acta Chem. Scand., 1950; 4:22.
Glucose oxidase activity was measured using the method of Bergmeyer et al,
Methods of Enzymatic Analysis, 1974; 1: 457 (Academic Press).
The results were compared to those obtained with the same reagent stored at
4oC. for 2 weeks. The absorbance of the reagent was measured at 500
nm and a factor determined from the absorbance, obtained after reacting the
reagent with a 100 mmol/l glucose standard.
The formulations were also subjected to conditions of freezing and elevated
temperature to mimic the conditions that could result on shipping of the
reagent.
The reagents were subjected to two sets of test conditions; storage at
either -20oC. or +37oC. Each test cycle consisted of 3 days
at either -20oC. or 37oC., followed by 3 days at the normal
storage temperature of 4oC. The reagents were subjected to 3 cycles
for each test condition.
After completion, the stability of each reagent was determined by assessing
the linearity and the ability to obtain the correct value for a range of
quality control materials.
All glucose and enzyme assays were performed using an automated analyser.
Results
1) Enzyme activity
The concentrations of both glucose oxidase and horse-radish peroxidase were
measured in all reagents after 2 weeks at -20oC. The results are
shown in Table 1. Reagent D which did not contain Mops buffer had no
detectable glucose oxidase activity present and a decreased level of
peroxidase after freezing and thawing. The other 3 reagents containing
either solely Mops buffer at 2 different concentrations or Mops and
phosphate buffers combined retained their glucose oxidase and peroxidase
activity after freezing and thawing.
TABLE 1
% Peroxidase
% Gluc enzyme recovery enzyme recovery
Formulation +4oC. -20oC. +4oC. -20oC.
D 79 0 173 87
C 75 80 93 91
B 70 74 137 132
A 43 46 115 112
2) Linearity (Tables 2, 3 4)
All formulations when stored at +4oC. showed linearity to 22 mmol/l
of glucose. All formulations containing Mops buffer maintained their
linearity of 22 mmol/l after 3 cycles at -20oC. Formulation D,
without Mops buffer, was inactivated after 3 cycles and the glucose
concentration could not be determined. All formulations after 3 cycles at
+37oC. maintained their linearity.
TABLE 2
(+4oC. Shipping Study Cycle 3)
% SERUM CONTROL C % dev B % dev A % dev
10 2.35 2.33 -0.9% 2.42 3.0% 2.36 0.4%
20 4.29 4.27 -0.5% 4.35 1.4% 4.3 0.2%
30 6.64 6.62 -0.3% 6.73 1.4% 6.63 -0.2%
40 9.12 9.12 0.0% 9.26 1.5% 9.13 0.1%
50 11.26 11.37 1.0% 11.51 2.2% 11.38 1.1%
60 13.72 13.69 -0.2% 14.07 2.6% 13.77 0.4%
70 16.01 16.06 0.3% 16.29 1.7% 16.03 0.1%
80 18.55 18.54 -0.1% 18.92 2.0% 18.7 0.8%
90 20.66 20.6 -0.3% 20.79 0.6% 20.75 0.4%
100 22.96 22.89 -0.3% 23.43 2.0% 23.09 0.6%
TABLE 3
(-30oC. Shipping Study Cycle 3)
% SERUM CONTROL C % dev B % dev A % dev
10 2.35 2.31 -1.7% 2.43 3.4% 2.41 2.6%
20 4.29 4.22 -1.6% 4.34 1.2% 4.33 0.9%
30 6.64 6.6 -0.6% 6.77 2.0% 6.69 0.8%
40 9.12 9.06 -0.7% 9.19 0.8% 9.24 1.3%
50 11.26 11.34 0.7% 11.55 2.6% 11.44 1.6%
60 13.72 13.59 -0.9% 13.95 1.7% 13.82 0.7%
70 16.01 16.07 0.4% 16.34 2.1% 16.11 0.6%
80 18.55 18.51 -0.2% 18.94 2.1% 18.7 0.8%
90 20.66 20.63 -0.1% 20.83 0.8% 20.85 0.9%
100 22.96 22.89 -0.3% 23.33 1.6% 23.2 1.0%
TABLE 4
(+37oC. Shipping Study Cycle 3)
CONT. CONT.
% SERUM +4oC. C % dev B % dev A % dev
+37oC. % dev
10 2.35 2.28 -3.0% 2.34 -0.4% 2.47 5.1% 2.3 -2.1%
20 4.29 4.29 0.0% 4.29 0.0% 4.67 8.9% 4.26 -0.7%
30 6.64 6.6 -0.6% 6.64 0.0% 7.15 7.7% 6.62 -0.3%
40 9.12 9.21 1.0% 9.19 0.8% 10.07 10.4% 9.17 0.5%
50 11.25 11.51 2.2% 11.43 1.5% 12.46 10.7% 11.45 1.7%
60 13.72 13.9 1.3% 13.89 1.2% 15.3 11.5% 13.95 1.7%
70 16.01 16.21 1.2% 16.25 1.5% 17.77 11.0% 16.21 1.2%
80 18.55 18.81 1.4% 18.88 1.8% 20.6 11.1% 18.82 1.5%
90 20.66 21.08 2.0% 20.69 0.1% 23.04 11.5% 20.9 1.2%
100 22.96 23.41 2.0% 23.35 1.7% 25.75 12.2% 23.13 0.7%
3) Recovery of glucose in quality control serum (Tables 5, 6 and 7)
The formulations were tested against control serum samples. In the Tables,
Precie-Path and Precie-Norm are available from Roche Diagnostics, and the
multisera samples are available from Randox Laboratories.
All formulations gave acceptable values when stored at +4oC. After 3
cycles at -20oC., all Mops containing formulations gave values
within ranges and deviations of less than 3% from the control reagent stored
at 4oC. After 3 cycles at 37oC., all formulations gave
acceptable values for each control serum sample.
TABLE 5
(+4oC. stability)
SERUM CONTROL C B A Target Ranges
Precie-Path 14.86 14.68 14.86 14.55 14.5 12.3 . . .
16.7
Precie-Path 5.87 5.85 5.95 5.86 5.71 4.84 . . .
6.58
Multisera 094 SL 3.4 3.41 3.46 3.4 3.43 2.92 . . .
3.94
Multisera 100 UN 6.24 6.23 6.32 6.22 6.02 5.42 . . .
6.62
Multisera 200 SN 6.18 6.17 6.28 6.13 6.08 4.86 . . .
7.30
Randox Calibrator 5.77 5.79 5.85 5.75 5.55 n/a
TABLE 6
(-20oC. stability at 2 weeks)
SERUM CONTROL C B A Target Ranges
Precie-Path 14.86 14.59 14.94 14.71 14.5 12.3 . . .
16.7
Precie-Path 5.87 5.8 5.91 5.88 5.71 4.84 . . .
6.58
Multisera 094 SL 3.4 3.38 3.49 3.42 3.43 2.92 . . .
3.94
Multisera 100 UN 6.24 6.21 6.31 6.26 6.02 5.42 . . .
6.62
Multisera 200 SN 6.18 6.11 6.25 6.13 6.08 4.86 . . .
7.30
Randox Calibrator 5.77 5.79 5.86 5.78 5.55 n/a
TABLE 7
(+37oC. stability at 2 weeks)
CONT. CONT.
SERUM +4oC. C B A +37oC. Target
Ranges
Precie-Path 14.86 14.59 14.94 14.71 14.92 14.5 12.3 . . . 16.7
Precie-Path 5.87 5.8 5.91 5.88 5.86 5.71 4.84 . . . 6.58
Multisera 094 SL 3.4 3.38 3.49 3.42 3.42 3.43 2.92 . . . 3.94
Multisera 100 UN 6.24 6.21 6.31 6.26 6.28 6.02 5.42 . . . 6.62
Multisera 200 SN 6.18 6.11 6.25 6.13 6.21 6.08 4.86 . . . 7.30
Randox Calibrator 5.77 5.79 5.86 5.78 5.75 5.55 n/a
In summary, the use of Mops buffer as a sole buffer, or in combination
with phosphate buffer, maintains the function of the enzymes after freezing
and thawing.
Claim 1 of 8 Claims
What is claimed is:
1. A method for stabilising the activity of an enzyme selected from the
group consisting of glucose oxidase and horseradish peroxidase during
storage, said method comprising storing the enzyme in a zwitterionic buffer
solution wherein the enzyme is stored in said zwitterionic buffer solution
for at least three days.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|